CLAIMS:

1. A replication competent group B oncolytic adenovirus comprising a sequence of formula **(I)**:

$$5'ITR\text{-}B_1\text{-}B_A\text{-}B_2\text{-}B_X\text{-}B_B\text{-}B_Y\text{-}B_3\text{-}3'ITR$$

wherein:

B_1 comprises: E1A, E1B or E1A-E1B;

B_A comprises-E2B-L1-L2-L3-E2A-L4;

B_2 is a bond or comprises: E3;

B_X is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both;

B_B comprises L5;

B_Y comprises a transgene cassette comprising a transgene and a splice acceptor sequence; and

B_3 is a bond or comprises: E4,

wherein the transgene cassette is under the control of an endogenous promoter selected from the group consisting of E4 and major late promoter and wherein the transgene cassette comprises a therapeutic gene encoding material selected from the group consisting of an RNAi sequence, an antibody or binding fragment thereof, chemokines, cytokines, immunomodulator and enzymes.

2. A replication competent adenovirus according to claim 1, wherein the promoter is the major late promoter.
3. A replication competent adenovirus according to claim 1 or 2, wherein B_Y also comprises the sequence shown in SEQ ID NO: 11 or a DNA sequence that hybridizes thereto under stringent conditions.
4. A replication competent adenovirus according to any one of claims 1 to 3, wherein the splice acceptor is selected from CAGG, SEQ ID NO: 17 and SEQ ID NO: 18.
5. A replication competent adenovirus according to any one of claims 1 to 4, wherein the transgene cassette further comprises an internal ribosome entry sequence or a high self-cleavage efficiency 2A peptide.
6. A replication competent adenovirus according to any one of claims 1 to 5, wherein the transgene further comprises a Kozak sequence.
7. An adenovirus according to any one of claims 1 to 6, wherein the transgene cassette further comprises a polyadenylation sequence.
8. An adenovirus according to any one of claims 1 to 7, wherein the transgene cassette further comprises a restriction site at the 3'end of the DNA sequence and/or at the 5'end of the DNA sequence.
9. An adenovirus according to any of claims 1 to 8, wherein at least one transgene cassette encodes monocistronic mRNA, or a polycistronic mRA.

10. An adenovirus according to claim 1 to 9, wherein the antibody or binding fragment thereof is specific to OX40, OX40 ligand, CD27, CD28, CD30, CD40, CD40 ligand, CD70, CD137, GITR, 4-1BB, ICOS, ICOS ligand, CTLA-4, PD-1, PD-L1, PD-L2, VISTA, B7-H3, B7-H4, HVEM, ILT-2, ILT-3, ILT-4, TIM-3, LAG-3, BTLA, LIGHT, CD160, CTLA-4, PD-1, PD-L1, PD-L2.
11. An adenovirus according to any one of claims 1 to 10, wherein the encoded protein is a cytokine independently selected from the group comprising IL-1α, IL-1β, IL-6, IL-9, IL-12, IL-13, IL-17, IL-18, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-33, IL-35, IL-2, IL-4, IL-5, IL-7, IL-10, IL-15, IL-21, IL-25, IL-1RA, IFNα, IFNβ, IFNγ, TNFα, TGFβ, lymphotoxin α (LTA) and GM-CSF.
12. An adenovirus according to any one of claims 1 to 11, wherein the encoded protein is a chemokine independently selected from the group comprising IL-8, CCL5, CCL17, CCL20, CCL22, CXCL9, CXCL10, CXCL11, CXCL13, CXCL12, CCL2, CCL19, CCL21, CXCR2, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CXCR3, CXCR4, CXCR5 and CRTH2.
13. An adenovirus according to any one of claims 1 to 12, wherein the transgene is a reporter gene, for example sodium iodide symporter, intracellular metalloproteins, HSV1-tk, GFPs, luciferase or oestrogen receptor.
14. An adenovirus according to any one of claims 1 to 13, wherein the adenovirus is Ad11.
15. An adenovirus according to any one of claims 1 to 13, wherein the adenovirus is the virus known as EnAd shown in sequence ID No: 12.
16. An adenovirus according to any one of claims 1 to 15, wherein the virus comprises the sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ IS NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 73.
17. A composition comprising an adenovirus according to any one of claims 1 to 16.
18. An adenovirus of any one of claims 1 to 16 or a composition of claim 17, for use in treatment.